

Cheng-Ling Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6555013/publications.pdf>

Version: 2024-02-01

24
papers

417
citations

840585

11
h-index

752573

20
g-index

24
all docs

24
docs citations

24
times ranked

415
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased apoptosis and suburothelial inflammation in patients with ketamine-related cystitis: a comparison with non-ulcerative interstitial cystitis and controls. <i>BJU International</i> , 2013, 112, 1156-1162.	1.3	70
2	Intravesical botulinum toxin injections do not benefit patients with ulcer type interstitial cystitis. <i>Pain Physician</i> , 2013, 16, 109-16.	0.3	47
3	Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition. <i>PLoS ONE</i> , 2018, 13, e0198816.	1.1	34
4	Pathophysiology of benign prostate enlargement and lower urinary tract symptoms: Current concepts. <i>Tzu Chi Medical Journal</i> , 2017, 29, 79.	0.4	33
5	Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis. <i>Scientific Reports</i> , 2020, 10, 15218.	1.6	30
6	Long-Term Efficacy and Safety of Repeated Intravesical OnabotulinumtoxinA Injections Plus Hydrodistention in the Treatment of Interstitial Cystitis/Bladder Pain Syndrome. <i>Toxins</i> , 2015, 7, 4283-4293.	1.5	28
7	Urothelial Dysfunction, Suburothelial Inflammation and Altered Sensory Protein Expression in Men with Bladder Outlet Obstruction and Various Bladder Dysfunctions: Correlation with Urodynamics. <i>Journal of Urology</i> , 2016, 196, 831-837.	0.2	25
8	Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility. <i>Toxins</i> , 2016, 8, 82.	1.5	24
9	Long-term follow up and predictive factors for successful outcome of transurethral incision of the bladder neck in women with detrusor underactivity. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 807-813.	0.8	18
10	Histopathological characteristics of ketamine-associated uropathy and their clinical association. <i>Neurourology and Urodynamics</i> , 2018, 37, 1764-1772.	0.8	16
11	Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinumtoxinA injection in the treatment of interstitial cystitis refractory to conventional treatment—A prospective, randomized, clinical trial. <i>Neurourology and Urodynamics</i> , 2018, 37, 1467-1473.	0.8	13
12	Change of Detrusor Contractility in Patients with and without Bladder Outlet Obstruction at Ten or More Years of follow-up. <i>Scientific Reports</i> , 2019, 9, 18887.	1.6	12
13	Efficacy and safety of mirabegron, a β_3 -adrenoceptor agonist, in patients with detrusor hyperactivity and impaired contractility. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, O93-O97.	0.6	10
14	Female bladder neck dysfunction—A video urodynamic diagnosis among women with voiding dysfunction. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2020, 12, 278-284.	0.6	10
15	Changes in sensory proteins in the bladder urothelium of patients with chronic kidney disease and end-stage renal disease. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, O202-O208.	0.6	8
16	Current consensus and controversy on the diagnosis of male lower urinary tract symptoms/benign prostatic hyperplasia. <i>Tzu Chi Medical Journal</i> , 2017, 29, 6.	0.4	8
17	Current pharmacological and surgical treatment of underactive bladder. <i>Tzu Chi Medical Journal</i> , 2017, 29, 187.	0.4	7
18	Real-World Data Regarding Satisfaction to Botulinum Toxin A Injection into the Urethral Sphincter and Further Bladder Management for Voiding Dysfunction among Patients with Spinal Cord Injury and Voiding Dysfunction. <i>Toxins</i> , 2022, 14, 30.	1.5	6

#	ARTICLE	IF	CITATIONS
19	Tailoring Medication for Lower Urinary Tract Symptoms in Men Based on International Prostate Symptom Score Voiding to Storage Ratio. <i>Urology</i> , 2018, 120, 30-35.	0.5	5
20	Effect of videourodynamic subtypes on treatment outcomes of female dysfunctional voiding. <i>International Urogynecology Journal</i> , 2022, 33, 1283-1291.	0.7	5
21	Adding mirabegron after intravesical onabotulinumtoxinA injection improves therapeutic effects in patients with refractory overactive bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021, 13, 440-447.	0.6	3
22	Therapeutic Effects of Urethral Sphincter Botulinum Toxin A Injection on Dysfunctional Voiding with Different Videourodynamic Characteristics in Non-Neurogenic Women. <i>Toxins</i> , 2021, 13, 362.	1.5	3
23	Male patients with a higher frequency of nocturnal urinary episodes are more likely to benefit from alpha-blocker therapy for bothersome nocturia. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, O174-O179.	0.6	1
24	Therapeutic efficacy of mirabegron 25 mg monotherapy in patients with nocturia-predominant hypersensitive bladder. <i>Tzu Chi Medical Journal</i> , 2020, 32, 30.	0.4	1